Shalby Ltd (SHALBY) is currently trading at 165.89 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Shalby Limited is an Ahmedabad‑headquartered integrated healthcare group operating 15 hospitals with 2,300+ beds across India and a growing implant MedTech vertical, combining multi‑specialty hospital services and an in‑house implant manufacturing and distribution platform (SAT, SMT, SGT). The company also operates international OPDs and owns an implant facility in California. Q3 FY26 consolidated revenue was INR 2,794 million (down 0.6% YoY) with consolidated EBITDA of INR 375 million and consolidated net debt of INR 4,086 million; standalone hospital EBITDA and PBT declined materially QoQ and YoY, highlighting near‑term margin pressure at hospital operations despite steady ARPOB and improving PAT. Annualized ROCE stands at 6.7% consolidated. Shalby MedTech shows a clear turnaround: Q3 MedTech consolidated revenue grew 29% YoY to INR 303.8 million with EBITDA turning positive versus a prior loss, and 9M FY26 MedTech revenue up 47% YoY to INR 949 million, reflecting stronger India execution, improved supply chain and product launches across markets including North America, Japan and Southeast Asia. Clinical and technology investments are accelerating clinical mix and premium services: robotic orthopedic and multi‑specialty deployments, radiotherapy/PET‑CT installations, launch of liver, kidney and bone marrow transplant programs and national recognition on ICU standards. Management emphasizes leveraging these capabilities to raise ARPOB, occupancy and tertiary high‑margin volumes. Capital strategy is pragmatic: limited large new capex in next 12 months, focused investments (bunkers, robots, diagnostics), selective inorganic consolidation and intent to reduce net debt as MedTech and hospital cash flows improve, while targeting a meaningful ROCE uplift driven by operational leverage.

Over the past 52 weeks, Shalby Ltd has traded between a low of ₹125.70 and a high of ₹274.50. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Shalby Ltd has a market capitalization of approximately 1,767.58. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Shalby Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 47.26 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 1,767.58 Cr, Shalby Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Shalby Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Shalby Ltd is 47.26. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Shalby reported consolidated net profit of ₹18.32 crore for the quarter ended March 2026, compared with a net loss of ₹11.02 crore in the March 2025 quarter.